Articles

RSS

DASGIP AG, located in Juelich (Germany) and the South Korean marketing and sales firm of foreign scientific products, KDR Biotech, in Seoul have signed a cooperation agreement. Thus, KDR Biotech will hold the exclusive distribution of DASGIP Parallel Bioreactor Systems on the Korean market. First sales are already initiated.

Since its formation in 1981, KDR Biotech CO., LTD. has established to a specialist in distribution of cell culture, molecular biology, immunology products as well as instruments for the life sciences and medical research industries. Running an own research facility, Sekyung Bioscience Institute, the company is in closed contacts to major application fields of its distributed products. Today, the fast growing company covers the Korean market with 3 branch offices in Daejeon, Jeonju, Gwangju and further local distributors. Chung, Youn-Taek, Managing Director of KDR Biotech, appreciates the partnership with DASGIP as the leading provider of parallel bench top bioreactors. "By including the DASGIP products into our portfolio we are aiming at winning first class labs in the areas of screening, strain and cell line development as well as process development as new customers", states Chung, Youn-Taek.

DASGIP thereby expands its global presence. Counting nine of the ten worldwide leading biopharmaceutical companies to its customers, DASGIP truly can state to have establish hed the Parallel Bioreactor Systems in the North-American and the European market. Since 2007 the company has been working on its expansion towards the Asian market. CEO Thomas Drescher points out: "With SCRUM, Tokyo, and Quintech, Singapore, we already are well represented in Japan and Singapore. Now we are happy to have found a reliable partner to enter the Korean market as well".

About KDR Biotech
KDR Biotech was founded in 1981. Core business areas are the marketing and distribution of cell culture, molecular biology, immunology products as well as instruments for the life sciences and medical research industries. With its own research facility, Sekyung Bioscience Institute, founded in 1998, KDR Biotech is aiming at developing research reagents and instruments and, in cooperation with local universities, developing intractable disease drug and pharmaceuticals. Arnold M.J. Kim is CEO and Chairman, Youn-Taek, Chung, is Managing Director of KDR Biotech. With three branch offices in Daejeon, Jeonju, Gwangju and six distributors in major Korean cities KDR Biotech covers the Korean market thoroughly. The company is headquartered in Seoul, Korea. For more information visit www.kdr.co.kr.

About DASGIP
DASGIP AG was founded in 1991 and develops and manufactures advanced Parallel Bioreactor Systems for the cultivation of microbial and mammalian cells at bench top and pilot scale. Process engineers, scientists and product developers from biotechnological, pharmaceutical and chemical companies as well as research institutions use DASGIP Parallel Bioreactor Systems for their biotechnological processes and benefit from increased productivity, high reproducibility, and ease of scale up, resulting in accelerated product development cycles. DASGIP is located in Juelich (Germany) and Shrewsbury MA (USA). For more information visit www.dasgip.com.

SOURCE: DASGIP AG